Anupam Rasayan has commercialized Ethyl trifluoroacetate (ETFA) using its proprietary flow chemistry technology. This marks a global first, offering operational advantages and targeting a USD 500-600 million market. The move highlights the company's focus on high-barrier manufacturing.

Anupam Rasayan Commercializes ETFA via Proprietary Flow Chemistry

Anupam Rasayan India Ltd has achieved a global first by commercializing Ethyl trifluoroacetate (ETFA), a key fluorinated building block, using its proprietary continuous flow chemistry technology.

Reader Takeaway: Technological first-mover advantage in ETFA; market size is an estimate.

What just happened

Anupam Rasayan India Ltd announced the commercial-scale production of Ethyl trifluoroacetate (ETFA). This chemical intermediate is used in life sciences, pharmaceuticals, and performance materials. The company highlights that it is the first globally to commercialize ETFA using continuous flow chemistry, a proprietary process.

Why this matters

This commercialization signifies Anupam Rasayan's technological advancement and entry into a new product segment. The proprietary flow chemistry process offers advantages like enhanced safety, reproducibility, scalability, efficiency, and a lower environmental footprint compared to traditional batch methods. The company is targeting a global addressable market for ETFA estimated at USD 500-600 million.

The backstory

As of March 31, 2026, Anupam Rasayan operates eight manufacturing facilities with a total installed capacity of 66,000 MT, spread across India (30,000 MT) and the USA (36,000 MT) through its Jayhawk Fine Chemicals acquisition. The company serves over 75 customers, including 31 multinational corporations, in specialty chemicals for life sciences and performance materials.

What changes now

The company is leveraging its technological edge and production scale to capture a share of the ETFA market. This move represents a strategic step towards higher-value specialty chemicals, differentiating Anupam Rasayan from competitors relying on conventional processes.

Risks to watch

The primary watch point is the estimated USD 500-600 million global addressable market for ETFA. This figure is an estimate and could be subject to market fluctuations and adoption rates.

Peer comparison

While the filing does not detail specific peers for ETFA production, Anupam Rasayan's use of proprietary flow chemistry for commercial-scale ETFA production positions it uniquely. Competitors typically utilize conventional batch processes for such intermediates.

Context metrics (time-bound)

As of March 31, 2026, Anupam Rasayan's total installed manufacturing capacity stood at 66,000 MT across eight facilities, with 30,000 MT in India and 36,000 MT in the USA.

What to track next

Investors will be keen to track the commercial success and revenue contribution of ETFA as it gains traction in domestic and international markets. Monitoring the adoption rate and any further technological advancements in fluorination chemistry will be crucial.